%0 Journal Article
%A Goldschmidt, Hartmut
%A Mai, Elias K
%A Dürig, Jan
%A Scheid, Christof
%A Weisel, Katja C
%A Kunz, Christina
%A Bertsch, Uta
%A Hielscher, Thomas
%A Merz, Maximilian
%A Munder, Markus
%A Lindemann, Hans-Walter
%A Hügle-Dörr, Barbara
%A Tichy, Diana
%A Giesen, Nicola
%A Hose, Dirk
%A Seckinger, Anja
%A Huhn, Stefanie
%A Luntz, Steffen
%A Jauch, Anna
%A Elmaagacli, Ahmet
%A Rabold, Bernhard
%A Fuhrmann, Stephan
%A Brossart, Peter
%A Goerner, Martin
%A Bernhard, Helga
%A Hoffmann, Martin
%A Hillengass, Jens
%A Raab, Marc S
%A Blau, Igor W
%A Hänel, Mathias
%A Salwender, Hans J
%T Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial.
%J Leukemia
%V 34
%N 7
%@ 1476-5551
%C London
%I Springer Nature
%M DKFZ-2020-00358
%P 1853-1865
%D 2020
%Z 2020 Jul;34(7):1853-1865
%X The MM5 trial aimed at demonstrating a progression-free survival (PFS) difference in continued vs. response-adapted (in case of complete response, CR) lenalidomide (LEN) maintenance therapy (MT) in newly diagnosed, transplant-eligible multiple myeloma (MM). Patients were equally randomized to receive induction therapy with PAd (bortezomib/doxorubicin/dexamethasone) or VCD (bortezomib/cyclophosphamide/dexamethasone), high-dose melphalan and autologous blood stem cell transplantation, and LEN consolidation, followed by either LEN MT for a fixed duration of 2 years (LEN-2Y) or until achievement of CR (LEN-CR, intention-to-treat population n = 502): arms A1:PAd + LEN-2Y (n = 125), B1:PAd + LEN-CR (n = 126), A2:VCD + LEN-2Y (n = 126), B2:VCD + LEN-CR (n = 125). In the LEN-CR group (B1 + B2), n = 88/17.5
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:32034285
%R 10.1038/s41375-020-0724-1
%U https://inrepo02.dkfz.de/record/153635